Full Press Release Details
by AgeX Therapeutics, Inc.
to Rule 425 under the
Act of 1933, as amended,
deemed filed pursuant to Rule 14a-12
the Securities Exchange Act of 1934, as amended
Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer
AL - November 17, 2023 (GlobeNews Wire) - Serina Therapeutics, Inc. (Serina), a privately held, clinical stage biotechnology company
focused on developing its proprietary POZ Platform TM drug delivery technology, including POZ lipid nanoparticle (LNP) delivery
systems for RNA-based therapeutics, today announced Serina has entered into a License Agreement under which Pfizer Inc. will license,
on a non-exclusive basis, Serina's POZ polymer technology.
are excited about the license to Pfizer for its use of the POZ polymer technology in initial research and development activities,"
stated Dr. Milton Harris, Executive Board Chair at Serina Therapeutics. "The license agreement represents an important milestone
is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases
and pain. Serina's POZ PlatformTM delivery technology is engineered to provide greater control in drug loading and more
precision in the rate of release of attached drugs, enabling the potential of challenging small molecules, while addressing the limitations
of PEG (polyethylene glycol) and other biocompatible polymers. Our POZ PlatformTM partners are at the forefront in advancing
LNP delivery technology to develop novel RNA therapeutics. Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha
Institute of Biotechnology. For more information, please visit https://serinatherapeutics.com.
release contains forward-looking statements about the potential of Serina's POZ polymer technology and LNP technology and the license
agreement with Pfizer, that involve substantial risks and uncertainties that could cause actual results to differ materially from those
expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research
and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials,
regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data
and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments
by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies;
whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities
may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on
a myriad of factors, including making a determination as to whether the product's benefits outweigh its known risks and determination
of the product's efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions
by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability
or commercial potential of any drug or vaccine candidates; whether the agreement between Serina and Pfizer will be successful; Serina's
ability to consummate the proposed merger of Serina with a wholly-owned subsidiary of AgeX Therapeutics, Inc. (NYSE American: AGE) ("AgeX");
uncertainties regarding the impact of COVID-19 on Serina's business, operations and financial results; and competitive developments.
The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements
contained in this release as the result of new information or future events or developments.
Information and Where to Find It
connection with the proposed merger transaction between Serina and AgeX, AgeX filed with the Securities and Exchange Commission (the
"SEC") a registration statement on Form S-4 on November 14, 2023 (the "Form S-4"). The Form S-4 contains a preliminary
proxy statement/prospectus of AgeX and a preliminary information statement of Serina (the "Preliminary Proxy Statement/Prospectus/Information
Statement"). The Preliminary Proxy Statement/Prospectus/Information Statement is not final and may be further amended. INVESTORS
AND STOCKHOLDERS ARE URGED TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT AGEX, SERINA AND THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and stockholders will be able to
obtain free copies of the Form S-4 and other documents filed by AgeX with the SEC (as they become available) through the website maintained
by the SEC at www.sec.gov. In addition, investors and stockholders will be able to obtain free copies of the Form S-4 and other
documents filed by AgeX with the SEC by contacting Andrea Park at AgeX by email at information@agexinc.com. Investors and stockholders
are urged to read the Form S-4, including the proxy statement/prospectus contained therein, and the other relevant materials as they
become available before making any voting or investment decision with respect to the proposed merger transaction.
and AgeX, and each of their respective directors and executive officers and certain of their other members of management and employees,
may be deemed to be participants in the solicitation of proxies in connection with the proposed merger transaction. Information about
AgeX's directors and executive officers is included in AgeX's Annual Report on Form 10-K for the year ended December 31,
2022, filed with the SEC on March 31, 2023, in the proxy statement for AgeX's 2022 annual meeting of stockholders, filed with the
SEC on November 2, 2022, and in AgeX's Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2023, filed
with the SEC on November 14, 2023. Additional information regarding these persons and their interests in the transaction is included
in the Preliminary Proxy Statement/Prospectus/Information Statement included in the Form S-4 relating to the transaction that was initially
filed with the SEC on November 14, 2023. These documents can be obtained free of charge from the sources indicated above.
Offer or Solicitation
communication relates to a proposed merger transaction between AgeX and Serina. This communication is for informational purposes only
and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval,
in any jurisdiction, pursuant to the proposed merger transaction or otherwise, nor shall there be any sale, issuance, exchange or transfer
of the securities referred to in this communication in any jurisdiction in contravention of applicable law. No offer of securities shall
be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.
Therapeutics Contact: